Previous 10 | Next 10 |
Six clinical-stage molecules targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b), HIF-2a and PD-1 continue to advance Multiple datasets are expected in 2022, including presentations planned for domvanalimab and etrumadenant in 1L PD-L1 high non-small cell lung cancer...
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced the closing of Gilead’s option exercises to three programs in Arcus’s clinical-stage portfolio and a new research collaboration between the two companies. On November 17, 2021, Gi...
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced the closing of Gilead’s option exercises to three programs in Arcus’ clinical-stage portfolio and a new research collaboration between the two companies. On November 17, 2021, Gil...
SALT LAKE CITY, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the promotion of Nicole Lambert to chief operating officer (COO). In her new role, she will continue to report directly to Paul J. Dia...
Shares of the cancer specialist Arcus Biosciences (NYSE: RCUS) jumped by approximately 31% during the month of November, according to data from S&P Global Market Intelligence . The biotech's shares ripped higher last month in response to Gilead Sciences (NASDAQ: GILD) ...
Taiho Pharmaceutical has exercised its option for two anti-TIGIT antibodies, domvanalimab (AB154) and AB308, from Arcus Biosciences (NYSE:RCUS), the companies announced on Tuesday. Domvanalimab is an Fc-silent anti-TIGIT antibody, and AB308 is an Fc-enabled anti-TIGIT antibody currently under...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, and Taiho Pharmaceutical Co., Ltd., (“Taiho”), an R&D driven specialty pharma compan...
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that management will participate in a fireside chat at the upcoming Evercore ISI HealthCONx...
Check Out These 4 Trending Biotech Stocks Right Now Biotech stocks have been among the most exciting stocks to invest in the stock market . The reason being, this is a high-risk, high-reward industry that could appeal to a certain group of investors. The stock movement within th...
Shares of Arcus Biosciences Inc. (NYSE:RCUS) traded at a new 52-week high today of $48.26. Approximately 407,000 shares have changed hands today, as compared to an average 30-day volume of 546,000 shares. In the past 52 weeks, shares of Arcus Biosciences Inc. have traded between a low of...
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8 th , 2024 at 2 PM...
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...